LYPHF Stock Chart & Stats
$0.27
-$0.05(-14.80%)
At close: 4:00 PM EDT
$0.27
-$0.05(-14.80%)
Day’s Range― - ―
52-Week Range$0.20 - $0.41
Previous CloseN/A
Volume2.50K
Average Volume (3M)0.00
Market Cap
$803.71M
Enterprise Value$9.44B
Total Cash (Recent Filing)$10.76B
Total Debt (Recent Filing)$12.54B
Price to Earnings (P/E)7.8
Beta-0.17
Next Earnings
Mar 31, 2027EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend Yield2.17%
Share Statistics
EPS (TTM)0.17
Shares Outstanding3,994,515,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.67
Price to Book (P/B)0.60
Price to Sales (P/S)1.52
P/FCF Ratio12.29
Enterprise Value/Market Cap11.75
Enterprise Value/Revenue1.54
Enterprise Value/Gross Profit2.42
Enterprise Value/Ebitda4.93
Forecast
1Y Price Target
$0.30Price Target Upside10.01% Upside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.02
Revenue Forecast (FY)$785.70M
Bulls Say, Bears Say
Bulls Say
Strong Operating MarginsHigh gross, EBIT, and EBITDA margins show that Luye Pharma retains substantial economics from its branded and specialty medicines. If maintained, this profitability provides internal funding for research, commercialization, and product life-cycle management while supporting resilience against competitive pricing pressure.
Improving Balance SheetThe reduction in debt-to-equity and expansion of equity indicate a more manageable capital structure than in earlier years. Lower leverage can improve financial flexibility, reduce balance-sheet risk, and leave the company better positioned to support operations and longer-term pharmaceutical investment.
Differentiated Specialty PortfolioA focus on branded medicines across oncology, cardiovascular and metabolic disease, and CNS disorders gives Luye Pharma exposure to specialized therapeutic needs. Proprietary delivery and formulation technologies can support differentiated products and life-cycle variants beyond basic commodity competition.
Bears Say
Sharp Revenue ContractionThe steep 2025 revenue decline raises a fundamental question about demand durability and the sustainability of the current profit base. Even with healthy margins, a smaller revenue platform can limit operating leverage, reduce reinvestment capacity, and weaken the consistency of future earnings.
Volatile Free Cash FlowThe return to positive free cash flow in 2025 is encouraging, but large swings across years reduce confidence in dependable cash generation. Moderate 2025 conversion of roughly 44% of net income also suggests reported profits have not consistently translated into cash available for reinvestment or returns.
Low Return On EquityLow return on equity indicates that the enlarged equity base is producing limited bottom-line efficiency. This weak capital productivity can constrain the compounding value of retained earnings and suggests that strong operating margins have not yet translated into proportionately strong shareholder returns.
Luye Pharma Group News
LYPHF FAQ
What was Luye Pharma Group Ltd.’s price range in the past 12 months?
Luye Pharma Group Ltd. lowest stock price was $0.20 and its highest was $0.41 in the past 12 months.
What is Luye Pharma Group Ltd.’s market cap?
Luye Pharma Group Ltd.’s market cap is $803.71M.
When is Luye Pharma Group Ltd.’s upcoming earnings report date?
Luye Pharma Group Ltd.’s upcoming earnings report date is Mar 31, 2027 which is in 153 days.
How were Luye Pharma Group Ltd.’s earnings last quarter?
Luye Pharma Group Ltd. released its earnings results on Aug 30, 2026. The company reported $0.004 earnings per share for the quarter, missing the consensus estimate of $0.007 by -$0.004.
Is Luye Pharma Group Ltd. overvalued?
According to Wall Street analysts Luye Pharma Group Ltd.’s price is currently Undervalued.
Does Luye Pharma Group Ltd. pay dividends?
Luye Pharma Group Ltd. pays a Annually dividend of $0.008 which represents an annual dividend yield of 2.17%. See more information on Luye Pharma Group Ltd. dividends here
What is Luye Pharma Group Ltd.’s EPS estimate?
Luye Pharma Group Ltd.’s EPS estimate is <0.01.
How many shares outstanding does Luye Pharma Group Ltd. have?
Luye Pharma Group Ltd. has 3,994,515,900 shares outstanding.
What happened to Luye Pharma Group Ltd.’s price movement after its last earnings report?
Luye Pharma Group Ltd. reported an EPS of $0.004 in its last earnings report, missing expectations of $0.007. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Luye Pharma Group Ltd.?
Currently, no hedge funds are holding shares in LYPHF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Luye Pharma Group Ltd.
Luye Pharma Group Ltd. functions as a global investment holding enterprise, focusing on the worldwide development, production, marketing, and sales of pharmaceutical products. The company's diverse portfolio includes several key oncology treatments: Lipusu for ovarian and breast cancers; CMNa, a chemical sensitizer used in cancer radiotherapy; Tiandida, targeting ovarian or non-small cell lung cancer; and Boyounuo, an injectable medication for various cancers and solid tumors. It also offers Yitaida for acute promyelocytic leukemia and liver cancer, and Lutingnuo, a glutathione injection for combating toxicity and injuries from ionizing radiation. Tiandixin serves as an adjuvant therapy for malignant tumors, hydrothorax, ascites, and respiratory infections. In the metabolic and cardiovascular health sector, Luye Pharma provides Xuezhikang, a lipid-regulating drug for hypercholesterolemia; Beitangning, a pioglitazone hydrochloride capsule for blood glucose control; and Beixi, an acarbose capsule for Type 2 diabetes. For neurological conditions and pain management, offerings include Maitongna, indicated for cerebral edema caused by trauma or surgery, and for venous reflux disorders. Transdermal patches such as Rivastigmine are available for Alzheimer's disease, Fentanyl for cancer pain, and Buprenorphine for chronic pain relief. Additionally, Seroquel and Seroquel XR are provided for treating schizophrenia and manic episodes associated with bipolar affective disorders. Rykindo, an injection for schizophrenia, is also part of their neurological therapeutics. Further therapeutic solutions span various conditions: Nuosen for acute upper digestive tract hemorrhage; Sailimai for diarrhea treatment; and the Apleek Transdermal Patch for contraception. Addressing musculoskeletal and inflammatory issues, the company offers Sidinuo for osteoporosis, Glucosamine hydrochloride tablets for osteoarthritis, Oulai (a compound sodium aescinate gel) for localized swelling, Oukai for soft tissue swelling and venous edema, and Fengshiye for pain in bones, joints, and limbs. Beyond product development, Luye Pharma Group actively engages in the distribution and commercialization of its pharmaceutical drugs, along with the manufacturing and sale of biopharmaceutical products. The company was established in 1994 and is headquartered in Yantai, People's Republic of China.
LYPHF Stock 12 Month Forecast
Average Price Target
$0.30
▲(10.01% Upside)
Technical Analysis
CSPC Pharmaceutical Group
―
Zai Lab Ltd
―
Consun Pharmaceutical Group Ltd.
―
Lepu Biopharma Co. Ltd. Class H
―
CStone Pharmaceuticals
―
Ownership Overview
3.04% Insiders
2.46% Mutual Funds
― Other Institutional Investors
90.95% Public Companies and
Individual Investors